Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition

Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition

Abstract Background Acute myeloid leukemia (AML) remains a therapeutic challenge due to drug resistance and relapse. Selinexor, an XPO1 inhibitor, shows limited efficacy as monotherapy, necessitating combination strategies. JQ1, a BET inhibitor targeting MYC, may synergize with Selinexor to enhance...

Full description

Saved in:

Bibliographic Details
Main Authors:	Pei-Hong Wang, Chu-Hong Hu, Jia-Qi Fan, Jia-Jun He, Ting-Fen Deng, Yan-Li Xu, Yu-Jun Dai, Shun-Qing Wang
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Series:	Journal of Translational Medicine
Subjects:	JQ1 Selinexor AML C-MYC MLL-AF9 bone marrow transplantation model PDX mouse model
Online Access:	https://doi.org/10.1186/s12967-025-06525-z
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation
by: Manman Deng, et al.
Published: (2025-07-01)

Gene expression profiling of patient‐derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts
by: Benjamin Bian, et al.
Published: (2017-03-01)

The BET inhibitor JQ1 targets fat metabolism and counteracts obesity
by: Claudia Fornelli, et al.
Published: (2025-02-01)

Selinexor in acute myeloid leukemia: therapeutic applications and current challenges
by: Ziyu Qie, et al.
Published: (2025-05-01)

Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease
by: Junjing Yin, et al.
Published: (2024-11-01)

A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma
by: Omar Alhalabi, et al.
Published: (2025-02-01)

Therapeutic Potential of Venetoclax and Selinexor in Targeting Hypoxia‐Induced Vulnerabilities in Multiple Myeloma
by: Seiichi Okabe, et al.
Published: (2025-06-01)

A combination of Dihydroartemisinin and Venetoclax enhances antitumor effect in AML via C-MYC/BCL-XL/MCL-1 triple targeting
by: Fenglin Li, et al.
Published: (2025-04-01)

MYC alterations in multiple myeloma: Genetic insights and prognostic impact
by: Sara Cristóbal-Vargas, et al.
Published: (2025-08-01)

Selinexor’s Immunomodulatory Impact in Advancing Multiple Myeloma Treatment
by: Kereshmeh Tasbihi, et al.
Published: (2025-03-01)

Congenital Acute Myeloid Leukemia (AML): A Case Report
by: Alsharidah S, et al.
Published: (2025-05-01)

Real-World Treatment Patterns and Survival Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with a Selinexor-Containing Triplet-Based Regimen
by: Andrew Whiteley, et al.
Published: (2025-05-01)

Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports
by: Yunshuo Xiao, et al.
Published: (2024-12-01)

Targeting deubiquitinase USP7-mediated stabilization of XPO1 contributes to the anti-myeloma effects of selinexor
by: Junying Wang, et al.
Published: (2025-01-01)

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation
by: Daniel Busa, et al.
Published: (2025-05-01)

Quantification of Total and Unbound Selinexor Concentrations in Human Plasma by a Fully Validated Liquid Chromatography-Tandem Mass Spectrometry Method
by: Suhyun Lee, et al.
Published: (2025-07-01)

Targeting MYC: Multidimensional regulation and therapeutic strategies in oncology
by: Yingying Duan, et al.
Published: (2025-07-01)

Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7‐driven Small Cell Lung Cancer
by: Tingting Qin, et al.
Published: (2025-04-01)

Relation between Genomic DNA Breakpoints in MLL Gene and Treatment Outcome in Infants with Acute Leukemia
by: GA Tsaur, et al.
Published: (2016-01-01)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study
by: Jing Li, et al.
Published: (2025-05-01)

Rethinking MYC inhibition: a multi-dimensional approach to overcome cancer’s master regulator
by: Jing Yu, et al.
Published: (2025-04-01)

Beyond the Limit: MYC Mediates Tumor Immune Escape
by: Zhongyang Hong, et al.
Published: (2025-06-01)

Unequal Genetic Redundancies Among MYC bHLH Transcription Factors Underlie Seedling Photomorphogenesis in Arabidopsis
by: Vikas Garhwal, et al.
Published: (2025-02-01)

c-Myc Inhibition Induces an Additive Effect with Cyclophosphamide in Acute Lymphoblastic Leukemia
by: Mohammad Sadeghi, et al.
Published: (2024-08-01)

PAK4 phosphorylates and stabilizes MYC to promote acute myeloid leukemia
by: Ting Xie, et al.
Published: (2025-10-01)

Enhancer Profiling Reveals a Protective Role of RXRα Against Calcium Oxalate‐Induced Crystal Deposition and Kidney Injury
by: Yu Yang, et al.
Published: (2025-06-01)

Galectin-3 Release in the Bone Marrow Microenvironment Promotes Drug Resistance and Relapse in Acute Myeloid Leukemia
by: Cansu Yıldırım
Published: (2025-06-01)

Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review
by: Chen B, et al.
Published: (2025-04-01)

Collaboration of Hprt/K-RAS/c-Myc mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study
by: Mai O Kadry, et al.
Published: (2024-12-01)

IMPDH inhibition activates TLR‐VCAM1 pathway and suppresses the development of MLL‐fusion leukemia
by: Xiaoxiao Liu, et al.
Published: (2022-12-01)

MYC target gene activation in chronic lymphocytic leukemia and richter transformation: links to aggressiveness and tumor microenvironment interactions
by: M. Tsagiopoulou, et al.
Published: (2025-08-01)

Clinical and biological features of acute myeloid leukemia with MLL gene rearrangements in children and results of therapy according to protocols AML-MM-2000/2006 in the Republic of Belarus
by: Yu. A. Barovskaya, et al.
Published: (2019-01-01)

A new inducible model for t(8;21) AML
by: James C. Mulloy
Published: (2013-11-01)

Regulatory role of transcription factor c-Myc in the pathogenesis of psoriasis
by: Yue Cao, et al.
Published: (2025-07-01)

Acute promyelocytic leukemia relapsing into acute myeloid leukemia-M2 with normal cytogenetics
by: Ranjit Kumar Sahoo, et al.
Published: (2013-01-01)

Oxidative stress enhances the therapeutic action of a respiratory inhibitor in MYC‐driven lymphoma
by: Giulio Donati, et al.
Published: (2023-05-01)

MYC and the unfolded protein response in cancer: synthetic lethal partners in crime?
by: Tingting Zhang, et al.
Published: (2020-04-01)

Detection of 11q23 (MLL) rearrangements in infant acute lymphoblastic leukemia
by: G. A. Tsaur, et al.
Published: (2014-07-01)

Translocation t(1;11)(p32;q23) with MLL-EPS15 fusion gene formation in acute leukemias: a review and 6 new case reports. Approaches to minimal residual disease monitoring
by: G. A. Tsaur, et al.
Published: (2014-07-01)

Clinical and molecular-biologic features of infant acute leukemia
by: Y. S. Korkina, et al.
Published: (2022-04-01)